FDA (CDER)
GUIDANCE DRAFT
Development of Non-Opioid Analgesics for Chronic Pain
Published: 5/13/2026Detected: 3/20/2026
Summary preview
Sets out a draft regulatory approach for developing non-opioid analgesics intended for chronic pain, which may influence study design expectations, benefit–risk assessment, and how safety outcomes are characterized for…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountneurology
psychiatry
clinical
safety
labeling
manufacturing
quality
#chronic pain
#analgesics
#non-opioid
#clinical development
#adverse events
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026